secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001723128-24-000037
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q3 revenue up 13% to $702M; GAAP net loss $0.2M, adjusted EPS $0.16; affirms guidance
--------------------------------------------------------------------------------

- Revenue $702M (+13% YoY); adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 YoY.
- GAAP net loss $0.2M vs net income $10M in Q3 2023; diluted EPS $0.00.
- Generics +9%, Specialty +19%, AvKARE +21%; launched CREXONT for Parkinson's disease.
- Collaboration with Metsera for obesity/metabolic drugs; in-licensed high-value biosimilar.
- Affirms full-year 2024 guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312824000037/0001723128-24-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312824000037/amrx-q32024x8k.htm
  HTML page:      https://secwatch.observer/filing/0001723128-24-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer